Cellectis (France) Executives
| ALCLS Stock | EUR 1.93 0.02 1.05% |
Cellectis employs about 294 people. The company is managed by 10 executives with a total tenure of roughly 55 years, averaging almost 5.0 years of service per executive, having 29.4 employees per reported executive. Discussion of Cellectis' management performance can provide insight into the enterprise performance.
| Andre Choulika Chairman Chairman of the Board and CEO, Member of the Executive Committee |
Cellectis |
Cellectis Management Team Effectiveness
The company has return on total asset (ROA) of (0.2408) % which means that it has lost $0.2408 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.557) %, meaning that it generated substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities.Cellectis Workforce Comparison
Cellectis is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 744. Cellectis totals roughly 294 in number of employees claiming about 40% of equities under Health Care industry.
Cellectis Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cellectis Price Series Summation is a cross summation of Cellectis price series and its benchmark/peer.
Cellectis Notable Stakeholders
A Cellectis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cellectis often face trade-offs trying to please all of them. Cellectis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cellectis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Andre Choulika | Chairman of the Board and CEO, Member of the Executive Committee | Profile | |
| David Sourdive | Co-Founder, Executive VP of Corporate Devel. and Director | Profile | |
| MarieBleuenn Terrier | General Counsel, Member of the Executive Committee | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Valerie Cros | Principal Officer | Profile | |
| Kyung NamWortman | Ex Officer | Profile | |
| Philippe Duchateau | Chief Scientific Officer | Profile | |
| Pascalyne Wilson | Director Communications | Profile | |
| Jean Epinat | Chief Officer | Profile | |
| MSc MSc | Chief Officer | Profile |
About Cellectis Management Performance
The success or failure of an entity such as Cellectis often depends on how effective the management is. Cellectis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cellectis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cellectis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is based in Paris, France. CELLECTIS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 161 people.
Cellectis Workforce Analysis
Traditionally, organizations such as Cellectis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cellectis within its industry.Cellectis Manpower Efficiency
Return on Cellectis Manpower
| Revenue Per Employee | 194.9K | |
| Revenue Per Executive | 5.7M | |
| Net Loss Per Employee | 388.4K | |
| Net Loss Per Executive | 11.4M | |
| Working Capital Per Employee | 812.9K | |
| Working Capital Per Executive | 23.9M |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.